Taken together, these results indicate that GLTSCR1 might be a biomarker for BET inhibitor sensitivity and that GLTSCR1 deficiency caused by frameshift mutation results in BET inhibitor resistance in CRC. The gene discussed is BICRA; the disease is colorectal carcinoma.